Pharma CEO Martin Shkreli's $750-a-pill drug now has a $1-a-pill competitor

Almost a month after word got out that drug-company CEO Martin Shkreli had jacked up the price of a critical drug by more than 5,000%, a different kind of pharma company has stepped up to provide a cheaper alternative.

Imprimis Pharmaceuticals, a compounding pharmaceutical company, announced Thursday that it is now providing a customizable formulation to compete with Daraprim, a drug used to treat a parasitic infection called toxoplasmosis in people with compromised immune systems.

What feeling does this article give you?

#hashtags to follow:

CEO Martin Shkreli [+]    Imprimis Pharmaceuticals [+]    Daraprim [+]   

More #news: